Cd38 Daratumumab Monoclonal Antibody
Chemical Information
|
Product name:Daratumumab |
Purity:95% min |
|
CAS NO:945721-28-8 |
Solubility:Soluble in DMSO |
|
Molecular Formula:C6466H9996N1724O2010S42 |
Package:Package according to customer requirements |
|
Molecular Weight:145,391.67 g/mol |
Storage:Store at -20℃ |
Quality control
Remarks
Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38,which multiple myeloma cells overexpress.Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. It was awarded orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
Related Prodcuts:
Pembrolimumab; Secukinumab; Infliximab; Ramucirumab; Ipilimumab; Atezolizumab; Dulaglutide; Rituximab; Adalimumab; Denosumab; Cetuximab; Bevacizumab
References
[1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.
[2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.